

Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

Naudin, Sabine; Solans Margalef, Marta; Saberi Hosnijeh, Fatemeh; Nieters, Alexandra; Kyrø, Cecilie; Tjønneland, Anne; Dahm, Christina C; Overvad, Kim; Mahamat-Saleh, Yahya; Besson, Caroline; Boutron-Ruault, Marie-Christine; Kühn, Tilman; Canzian, Federico; Schulze, Matthias B; Peppas, Eleni; Karakatsani, Anna; Trichopoulou, Antonia; Sieri, Sabina; Masala, Giovanna; Panico, Salvatore; Tumino, Rosario; Ricceri, Fulvio; Chen, Sairah Lai Fa; Barroso, Leila Luján; Huerta, José María; Sánchez, Maria-Jose; Ardanaz, Eva; Menéndez, Virginia; Amiano Exezarreta, Pilar; Spaeth, Florentin; Jerkeman, Mats; Jirstom, Karin; Schmidt, Julie A; Aune, Dagfinn; Weiderpass, Elisabete; Riboli, Elio; Vermeulen, Roel; Casabonne, Delphine; Gunter, Marc; Brennan, Paul; Ferrari, Pietro

Published in:
International Journal of Cancer

DOI (link to publication from Publisher):
[10.1002/ijc.32977](https://doi.org/10.1002/ijc.32977)

Publication date:
2020

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Naudin, S., Solans Margalef, M., Saberi Hosnijeh, F., Nieters, A., Kyrø, C., Tjønneland, A., Dahm, C. C., Overvad, K., Mahamat-Saleh, Y., Besson, C., Boutron-Ruault, M.-C., Kühn, T., Canzian, F., Schulze, M. B., Peppas, E., Karakatsani, A., Trichopoulou, A., Sieri, S., Masala, G., ... Ferrari, P. (2020). Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study. *International Journal of Cancer*, 147(6), 1649-1656. <https://doi.org/10.1002/ijc.32977>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: July 05, 2025

Healthy lifestyle and the risk of lymphoma in the EPIC study

(IJC-19-2849)

Sabine Naudin¹, Marta Solans Margalef^{2,3}, Fatemeh Saberi Hosnijeh⁴, Alexandra Nieters⁵, Cecilie Kyrø⁶, Anne Tjønneland^{6,7}, Christina C Dahm⁸, Kim Overvad^{8,9}, Yahya Mahamat-saleh^{10,11}, Caroline Besson^{10,12}, Marie-Christine Boutron-Ruault^{10,11}, Tilman Kühn¹³, Federico Canzian¹⁴, Matthias B. Schulze^{15,16}, Eleni Peppas¹⁷, Anna Karakatsani^{17,18}, Antonia Trichopoulou¹⁷, Sabina Sieri¹⁹, Giovana Masala²⁰, Salvatore Panico²¹, Rosario Tumino²², Fulvio Ricceri^{23,24}, Sairah Lai Fa Chen²⁵, Leila Luján Barroso²⁶, José María Huerta^{27,28}, Maria-Jose Sánchez^{28,29,30,31}, Eva Ardanaz^{28,32,33}, Virginia Menéndez³⁴, Pilar Amiano Exezarreta^{28,35}, Florentin Spaeth³⁶, Mats Jerkeman³⁷, Karin Jirstom³⁸, Julie A Schmidt³⁹, Dagfinn Aune^{40,41,42}, Elisabete Weiderpass⁴³, Elio Riboli⁴⁰, Roel Vermeulen⁴, Delphine Casabonne^{2,44}, Marc Gunter⁴⁵, Paul Brennan^{46#}, Pietro Ferrari^{1#*}

¹Nutritional Methodology and Biostatistics Group, International Agency for Research on Cancer, World Health Organization, Lyon, France; ²Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain; ³Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Girona, Spain; ⁴Institute for Risk Assessment Sciences, Division of Environmental Epidemiology, Utrecht University, Utrecht, The Netherlands; ⁵Research Group Epidemiology, Institute for Immunodeficiency, Medical Center-University of Freiburg, Freiburg, Germany; ⁶Danish Cancer Society Research Center, Copenhagen, Denmark; ⁷Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen; ⁸Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus, Denmark; ⁹Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark; ¹⁰CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, 94805, Villejuif, France; ¹¹Gustave Roussy, F-94805, Villejuif, France; ¹²Department of Hematology and Oncology, Hospital of Versailles, Le Chesnay, France; ¹³Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; ¹⁴Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; ¹⁵Department of Molecular Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany; ¹⁶Institute of Nutrition Science, University

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.32977

of Potsdam, Nuthetal, Germany; ¹⁷Hellenic Health Foundation, Athens, Greece; ¹⁸Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Haidari, Greece; ¹⁹Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy; ²⁰Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy; ²¹Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy; ²²Cancer Registry and Histopathology Department, Azienda Sanitaria Provinciale (ASP) Ragusa, Italy; ²³Department of Clinical and Biological Sciences, University of Turin, Italy; ²⁴Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco (TO), Italy; ²⁵Institutt for Samfunnsmedisin, Det Helsevitenskapelige fakultet, UiT, Norges arktiske universitet, Tromsø, Norway; ²⁶Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; ²⁷Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain; ²⁸Spanish Consortium for Research and Public Health (CIBERESP), Madrid, Spain; ²⁹Andalusian School of Public Health (EASP), Granada, Spain; ³⁰Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; ³¹Universidad de Granada (UGR), Granada, Spain; ³²Navarra Public Health Institute, Pamplona, Spain; ³³IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; ³⁴Public Health Directorate, Asturias, Spain; ³⁵Public Health Division of Gipuzkoa, Biodonostia Health Research Institute, Ministry of Health of the Basque Government, San Sebastian, Spain; ³⁶Department of Radiation Sciences, Oncology, Umeå University, Sweden; ³⁷Division of Oncology, Lund University, Malmö, Sweden; ³⁸Department of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Sweden; ³⁹Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; ⁴⁰Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom; ⁴¹Department of Nutrition, Bjørknes University College, Oslo, Norway; ⁴²Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway; ⁴³Office of the Director, International Agency for Research on Cancer, World Health Organization, Lyon, France; ⁴⁴Unit of Molecular and Genetic Epidemiology in Infections and Cancer, Catalan Institute of Oncology (ICO-IDIBELL),

L'Hospitalet de Llobregat, Spain; ⁴⁵Nutritional Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France; ⁴⁶Genetic Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.

Shared Senior Authorship.

***Corresponding Author**

Pietro Ferrari, PhD

Nutritional Methodology and Biostatistics Group

International Agency for Research on Cancer, WHO

150 cours Albert Thomas

69372 Lyon CEDEX 08, France

Tel. +33 472 738 031

E-mail: ferrarip@iarc.fr

Key words

Hodgkin lymphoma, non-Hodgkin lymphoma, healthy lifestyle index, EPIC, prospective study.

Abbreviations

HLI: healthy lifestyle index

CI: confidence interval

EPIC: European Prospective Investigation into Cancer and Nutrition

NHL: non-Hodgkin lymphoma

HL: Hodgkin lymphoma

BCL: mature B-cell lymphoma

MT/NK: mature T and natural killer-cell lymphoma

DLBCL: diffuse large B-cell lymphoma

FL: follicular lymphoma

CLL/SLL: chronic lymphocytic leukemia and small lymphocytic leukemia

PCN/MM: plasma cell neoplasm and multiple myeloma

HR: hazard ratio

Article category

Short Report, Cancer Epidemiology

Novelty and impact statements (Words=85)

Do lifestyle factors affect lymphoma risk? Previous studies have been inconclusive, and most lacked statistical power to allow accurate conclusions. In this large, prospective European study, the authors examined the relationship between a score combining lifestyle exposures, such as smoking, BMI, and alcohol, and the risk of lymphoma. They observed that healthy behaviors were inversely related to the risk of Hodgkin lymphoma, although smoking was the main driver of the association. These findings indicated a limited role for lifestyle factors in the etiology of lymphomas.

Accepted Article

Abstract (Words = 248)

Limited evidence exists on the role of modifiable lifestyle factors on the risk of lymphoma. In this work, the associations between adherence to healthy lifestyles and risks of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) were evaluated in a large-scale European prospective cohort. Within the European Prospective Investigation into Cancer and Nutrition (EPIC), 2,999 incident lymphoma cases (132 HL and 2,746 NHL) were diagnosed among 453,808 participants after 15 years (median) of follow-up. The healthy lifestyle index (HLI) score combined information on smoking, alcohol intake, diet, physical activity and BMI, with large values of HLI expressing adherence to healthy behavior. Cox proportional hazards models were used to estimate lymphoma hazard ratios (HR) and 95% confidence interval (CI). Sensitivity analyses were conducted by excluding, in turn, each lifestyle factor from the HLI score. The HLI was inversely associated with HL, with HR for a 1-standard deviation (SD) increment in the score equal to 0.78 (95%CI: 0.66, 0.94). Sensitivity analyses showed that the association was mainly driven by smoking and marginally by diet. NHL risk was not associated with the HLI, with HRs for a 1-SD increment equal to 0.99 (0.95, 1.03), with no evidence for heterogeneity in the association across NHL subtypes. In the EPIC study, adherence to healthy lifestyles was not associated with overall lymphoma or NHL risk, while an inverse association was observed for HL, although this was largely attributable to smoking. These findings suggest a limited role of lifestyle factors in the etiology of lymphoma subtypes.

Introduction (Words = 2,481)

Lymphoma comprises a heterogeneous group of malignancies occurring in the lymphatic system, traditionally grouped as Hodgkin (HL) and non-Hodgkin lymphoma (NHL),¹ which accounts for about 3.2% of cancers worldwide.² During recent decades, lymphomas incidence rates increased with relatively higher rates in high-income countries² and significant disparities among ethnic groups,³ suggesting an influence of lifestyle factors in lymphomagenesis that are more prevalent in the Western world.

Although the roles of lifestyle factors have been extensively investigated in association with solid neoplasms, evidence on lymphoma risk remains unclear.⁴ Obesity and alcohol consumption have been most consistently associated with lymphoma, with positive⁵ and inverse⁶ relationships, respectively. However, most studies, predominantly case-control, faced differential recall bias for the assessment of lifestyle habits and sample size limitations for the investigation of lymphoma subtypes. Additionally, lifestyle factors were often evaluated independently in etiological models.

In this study, a set of modifiable exposures, including smoking, alcohol intake, dietary habits, body mass index (BMI), and physical activity were combined into the Healthy Lifestyle Index (HLI) to reflect adherence to healthy habits. The HLI was previously related to the risks of site-specific and overall cancers in prospective studies.⁷ In this analysis, associations between the HLI and lymphoma risks were examined within the EPIC study. The contributing role of each component of the HLI to lymphoma risk was also investigated.

Methods

Study population. EPIC is a multicenter prospective study designed to investigate the etiology of cancer in relation to diet and lifestyle factors. From 1992 to 2000, a total of 521,324 participants (70% women, 35–70 years of age at baseline) were recruited in 10 European countries, mostly from the general population, as explained previously.⁸ In France, Norway, Utrecht and Naples, only women were recruited. Approval was obtained from IARC and participating institutions' ethical review boards and participants provided informed consent before completing questionnaires at baseline.

Ascertainment of outcome. Cancer cases were identified during follow-up based on population cancer registries in Denmark, Italy, Netherlands, Spain, Sweden, Norway and the United Kingdom, and on a combination of methods, including health insurance records, cancer and pathology registries, and active follow-up of EPIC participants and their next of kin in France, Naples, Germany, and Greece. Clinical and morphological data were standardized using a common protocol across centers.⁸ Mortality data were collected from cancer or mortality registries at the regional or national level.

The most recent vital status and cancer diagnosis update was used. Vital status was known for 98.4% of all EPIC subjects while 1.6% of participants had emigrated, withdrawn or were lost to follow-up. The follow-up period ended between June 2008 and December 2012 depending on the recruitment centers.⁷

Diagnoses of primary incident lymphoma cases were classified based on the International Classification of Diseases Oncology, 3rd edition (ICD-O-3), and grouped according to recommendations of the InterLymph Pathology Working Group,¹ as: Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and lymphoma not otherwise specified (NOS); within NHL as: mature B-cell lymphoma (BCL), mature T and natural killer-cell lymphoma (MT/NK) and other NHL; among BCL as: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL), multiple myeloma and plasma cell neoplasm (MM/PCN) and other BCL, as detailed in **Table 1**.

Exposure assessment. Habitual diet, including alcohol intake, during the year preceding recruitment was assessed at recruitment using validated center-specific self-reported dietary questionnaires.⁸ Data on anthropometry (self-reported in France and the UK Oxford center), physical activity, smoking habits, and prevalent chronic conditions were collected using lifestyle questionnaires.⁸

A diet score was built from the combination of six dietary factors reflecting diet quality,⁷ i.e. cereal fibers, red and processed meat, the ratio of polyunsaturated to saturated fatty acids, margarine (to express industrially produced trans-fats), glycemic load, and fruits and vegetables. For each dietary factor, country-specific residuals were computed in models with total energy intake, grouped into country-specific deciles and scored from 0 to 9 with 0 being

the least healthy (i.e. high intake of red meat/processed meat, margarine, and glycaemic load, and low intake of fruits and vegetables, cereal fibres, and ratio of polyunsaturated to saturated fatty acids). Individual scores were summed up and categorized into quintiles.

Definition of HLI. Scores of 0 to 4 were assigned to each individual variable category attributing larger values to the healthier behaviours for smoking (current smoking >15 cigarettes/day=0, current smoking ≤15 cigarettes/day=1, ex-smokers quit ≤10-years=2, ex-smokers quit >10 years=3, never smokers=4), alcohol consumption (in g/day) at recruitment (>48=0, 24–47.9=1, 12–23.9=2, 6–11.9=3, and <6 =4), diet score (1st quintile=0 to the 5th quintile=4), physical activity index (inactive=1, moderately inactive=2, moderately active=3, active=4), and body mass index at recruitment (BMI, kg/m²: >30=0, 26–29.9=1, <22=2, 24–25.9=3, 22–23.9=4). The final score was the arithmetic sum of the scores for each lifestyle factor and ranged from 1 to 20.

Statistical analysis.

The association between the HLI and the risk of lymphoma was evaluated using multivariable Cox proportional hazards models, with age as the primary time variable, and Breslow's method to handle ties. The time at study entry was the age at recruitment, while the exit time was defined as the age at cancer diagnosis, death, loss to, or end of follow-up, whichever occurred first. All models were stratified by country,⁹ age at recruitment in 1-year categories and sex.

The HLI was modelled as a continuous variable to compute HR estimates for a one-standard deviation (SD) corresponding to approximately 3 units in the score, and in quartiles using the second quartile as reference to avoid extreme comparisons within the HLI range. Models were systematically adjusted for education level (no degree/primary school, secondary/technical or professional school, longer education including university degree, unknown (4%)), height (cm, continuous), and energy intake from non-alcohol sources (kcal/day, continuous).

Overall tests for statistical significance of HRs were determined by comparing Wald-test statistics to a χ^2 distribution with three degrees of freedom (dof) for HLI in categories (p_{Wald}) and one dof in continuous (p_{trend}). The assumption of proportional hazards (PH) was evaluated through the Schoenfeld's residuals.¹⁰

Potential departure from linearity in the association between HLI and HL risk was evaluated using restricted cubic splines¹¹ and comparing the difference in log-likelihood of models with and without non-linear terms to a χ^2 distribution with two degrees of freedom.

Sensitivity analyses were carried out by excluding, in turn, each factor from the HLI scores to identify factors mostly driving associations with each lymphoma subtype. The excluded component was used as a confounder in the model. Relationships between the HLI and lymphoma risks (HL and NHL) were examined by, in turn, sex, European region (North: Denmark, Norway, Sweden; Central: United Kingdom, The Netherlands, Germany; South: France, Greece, Italy, and Spain), and age at recruitment (<50, 50–60, \geq 60 years old). Heterogeneity was evaluated by comparing the difference in log-likelihood of models with and without interaction terms between the HLI (continuous) and, in turn, sex, European region and age categories, to a χ^2 distribution with dof equal to the total number of interaction terms minus one. Heterogeneity of associations across BCL subtypes was evaluated through data-augmentation by comparing the difference in log-likelihood of models with and without an interaction term between the HLI and an indicator variable for BCL subtypes to a χ^2 distribution with four dof.¹² To address potential reverse causation, analyses were carried out excluding the first 2 and 5 years of follow-up.

Two-sided p-values were determined with nominal statistical significance set to 5%. Analyses were performed using Stata version 14.¹³

Data availability. Information to access EPIC data and/or biospecimens can be found at http://epic.iarc.fr/access/gain_access.php.

Results

Study participants without lifestyle or dietary information (n=6,902), with a ratio of estimated energy intake to energy requirement in the top or bottom 1% (n=10,241), with self-reported prevalent cancer (n=24,221), with missing follow-up information (n=3,800) and with missing smoking status (n=15,685) or physical activity (n=8,824) were excluded. From a total of 453,808 participants followed-up over 15 years (median), with a total of 6,328,639 person-years, 2,999 incident lymphoma cases were diagnosed, including 2,746 NHL, 132 HL and 121

lymphomas NOS (**Table 1**). The HLI components and the confounding variables are described in **Table 2**. HLI was positively related to level of education and showed higher values in women than men.

No association was observed between the HLI and the overall risk of lymphoma (**Table 3**). However, a 1-SD increase of HLI was inversely associated with HL risk (HR=0.78, 95%CI: 0.66, 0.94; $p_{\text{trend}} = 7.3\text{e-}03$). The HRs for HL risk comparing the first, third and fourth quartile to the second quartile were 1.21 (0.78, 1.86), 0.64 (0.37, 1.09), and 0.64 (0.37, 1.10), respectively, with a significant trend across categories ($p_{\text{wald}}=0.03$). The HLI was not associated with the risk of the major NHL subtypes (**Table 3**). The PH assumption was satisfied in each lymphoma subtype model.

The HLI and HL risk dose-response relationship using restricted cubic splines presented limited evidence of departure from linearity ($p_{\text{non-linearity}} = 0.42$) (**Online Supplementary Figure 1**).

Sensitivity analyses indicated that exclusion of smoking or diet from the HLI resulted in HL HRs for a 1-SD increase equal to 0.88 (95%CI: 0.71,1.10; $p_{\text{trend}}=0.27$) and 0.85 (0.69,1.04; $p_{\text{trend}}=0.12$), respectively (**Online Supplementary Table 1**). HRs for the other NHL subtypes were not altered after exclusion of, in turn, each lifestyle factors of the HLI.

The associations between the HLI and lymphoma risk did not show evidence of heterogeneity by sex, European region and age at recruitment (results not shown). No evidence for heterogeneity was found across BCL subtypes ($p_{\text{heterogeneity}}=0.20$). Exclusion of the first 2 and 5 years of follow-up did not materially alter HR estimates (**Online Supplementary Table 2**).

Discussion

In a large European prospective study, a score combining five lifestyle factors was not associated with the risk of NHL. An inverse relationship was observed for HL, where smoking and, to a lesser extent, diet were the main drivers of the association.

This study is one of the first attempts to investigate the risk of lymphoma with respect to modifiable lifestyle factors combined into a score. Within the NIH-AARP study, a score based on the American Cancer Society recommendations including physical activity, diet, BMI,

alcohol, but not smoking, yielded an inverse association between adherence to recommendations and HL risk. A 43% (95%CI: 2%,67%) lower risk of HL was observed when comparing the healthiest with the least healthy score category in an analysis including 113 HL cases, suggesting that lifestyle factors other than smoking may affect HL etiology, while no association was observed with NHL risk, consistently with findings in our study.¹⁴

Smoking has been consistently positively associated with HL risk,¹⁵ with chronic exposure to cigarette smoking believed to promote and support lymphogenic microenvironment and affect immune cells through the impairment of T cells, natural killer cells, B cells and macrophages.¹⁶ In our work, a comprehensive evaluation of the association between HLI and HL was undertaken via sensitivity analyses where each component of the lifestyle score was, in turn, removed from the HLI. Exclusion of smoking from HLI resulted in a null association suggesting that smoking was largely driving the association between lifestyle factors and HL risk.

Although diet has been inconsistently related to HL,¹⁷ recent EPIC studies showed that dietary patterns reflecting Mediterranean and anti-inflammatory potential of diet were inversely associated with HL risk.^{18,19} In our sensitivity analysis a null association was consistently observed after the exclusion of diet from the HLI score, suggesting that diet could be involved in the HLI-HL relationship. Plausible biological mechanisms relating HL pathology to diet may involve inflammation pathways, possibly reflecting, among other factors, a diet rich in saturated fat, refined grains, red and processed meat, and high glycemic load.^{17,20}

Cumulative evidence points towards a positive relationship between obesity and HL²¹ which could be the consequence of an alteration of the immune response and stimulate low-grade chronic inflammation in adipose tissue.⁵ Alcohol intake has been repeatedly inversely associated with risks of HL and NHL, particularly with DLBCL, CLL and FL subtypes,⁶ a result that was partially attributed to reverse causation, as early symptoms of lymphomas may lead individuals to either quit or reduce their alcohol intake.²²

Current evidence suggests a role of lifestyle factors with respect to several NHL subtype risks. While smoking has been positively related to T-cell NHL,¹⁵ obesity has been related to an increase in diffuse large B-cell lymphoma (DLBC) and multiple myeloma (MM) risks,⁵ and a pro-inflammatory diet was positively associated with mature B-cell NHL.¹⁸ In this study, HLI

was not associated with the risk of NHL, either overall or within any of the NHL subtypes. Although HLI was inversely associated with the group of 'other BCL' (HR for a 1-SD increase in the HLI: 0.88; 95% CI: 0.79,1.00; $p_{\text{trend}}=0.04$), the associations of HLI across BCL subtypes was not heterogeneous ($p_{\text{heterogeneity}}=0.20$). Despite the large size of the EPIC cohort, our study was possibly underpowered to detect likely weak associations of lifestyle habits with respect to lymphoma subtypes. Our results were not altered in sensitivity analyses that excluded, in turn, each lifestyle factor from the score.

The strength of the current study relies on its prospective multi-country design, which included study populations with heterogeneous lifestyle habits. Among the limitations, we note that EPIC participants represent a healthy proportion of the general population and that risk estimates in our study were likely attenuated. In addition, our analyses did not account for potential changes in lifestyle habits during follow-up, potentially introducing bias in association estimates. These changes may have been the result of incident morbid conditions in ageing study population. Reverse causation could have biased some of our findings, by inducing changes of lifestyle behaviors before recruitment as a result of early symptoms. To partially address this, associations were minimally affected after exclusion of the first two and five years of follow-up. Furthermore, as pathological techniques for lymphoma ascertainment have developed continuously over the last decades, some of the cases of lymphoma subtypes may have been misclassified or simply missed. However, the most recent recommendations for lymphoma ascertainment were used in our study.^{1,23} Education was used as a proxy for socioeconomic status in the adjustment of the models, which may introduce residual confounding. Furthermore, the HLI score considered a selected list of lifestyle factors, each of which was given an equal weight. Information on occupation, pesticide exposure, history of participants' infectious diseases (e.g. Human Immunodeficiency Virus, Epstein-Barr virus, and hepatitis viruses), which are known risk factors of lymphoma,^{24,25} would provide more informative insights of lymphoma etiology. However, information on these factors was available for a limited proportion of the EPIC cohort.

In summary, in a large prospective study of European adults, adherence to a combination of healthy lifestyle habits was not associated with the risk of NHL and was inversely related to the

risk of HL, with smoking largely driving this association. These findings suggest a limited role of lifestyle factors in the etiology of lymphoma subtypes. However, the HLI accounts for five lifestyle habits, and other environmental factors like pesticides and occupational exposures might be relevant to lymphoma etiology.

Financial disclosure

This work was supported by the Direction Générale de la Santé (French Ministry of Health) (Grant GR-IARC-2003-09-12-01), by the European Commission (Directorate General for Health and Consumer Affairs) and the International Agency for Research on Cancer. The national cohorts are supported by the Danish Cancer Society (Denmark); the Ligue Contre le Cancer, the Institut Gustave Roussy, the Mutuelle Générale de l'Éducation Nationale and the Institut National de la Santé et de la Recherche Médicale (France); the Deutsche Krebshilfe, the Deutsches Krebsforschungszentrum, and the Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation and the Hellenic Ministry of Health and Social Solidarity (Greece); the Italian Association for Research on Cancer and the National Research Council (Italy); the Dutch Ministry of Public Health, Welfare and Sports, the Netherlands Cancer Registry, LK Research Funds, Dutch Prevention Funds, the Dutch Zorg Onderzoek Nederland, the World Cancer Research Fund and Statistics Netherlands (the Netherlands); the Health Research Fund, Regional Governments of Andaluc ya, Asturias, Basque Country, Murcia (project 6236) and Navarra, Instituto de Salud Carlos III, Redes de Investigaci n Cooperativa (RD06/0020) (Spain); the Swedish Cancer Society, the Swedish Scientific Council and the Regional Government of Sk ne (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk, C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (MR/N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom), the Stroke Association, the British Heart Foundation, the Department of Health, the Food Standards Agency, and the Wellcome Trust (UK). This work was part of Sabine Naudin's PhD at Claude Bernard Lyon I University (France), funded by R gion Auvergne Rh ne-Alpes, ADR 2016 (France).

Conflict of interest

None to declare.

Acknowledgments

We thank Carine Biessy and Bertrand Hemon for their technical support and contribution to this work. We are also grateful to all the EPIC participants who have been part of the project and to the many other members of the study teams who have enabled this research.

Copyright statements

Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World Health Organization.

References

1. Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, Monnereau A, Maynadié M, Chiu BC-H, Marcos-Gragera R, Costantini AS, Cerhan JR, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood* 2010;116:e90–8.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 2018;68:394–424.
3. Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC-H. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. *Ann Oncol* 2012;23:2128–37.
4. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and pancreatic cancer. www.dietandcancerreport.org, 2018.
5. IARC. Absence of Excess Body Fatness / IARC Working Group on the Evaluation of Cancer-Preventive Interventions [Internet]. IARC Handbooks of Cancer Prevention, 2018. 658p Available from: <http://publications.iarc.fr/570>
6. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, Pelucchi C, Galeone C, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis. *Br J Cancer* 2015;112:580–93.
7. McKenzie F, Biessy C, Ferrari P, Freisling H, Rinaldi S, Chajès V, Dahm CC, Overvad K, Dossus L, Lagiou P, Trichopoulos D, Trichopoulou A, et al. Healthy Lifestyle and Risk of Cancer in the European Prospective Investigation Into Cancer and Nutrition Cohort Study. *Medicine (Baltimore)* 2016;95:e2850.

- Accepted Article
8. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondière UR, Hémon B, Casagrande C, Vignat J, Overvad K, Tjønneland A, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutrition* 2002;5:1113–24.
 9. Ferrari P, Day NE, Boshuizen HC, Roddam A, Hoffmann K, Thiébaud A, Pera G, Overvad K, Lund E, Trichopoulou A, Tumino R, Gullberg B, et al. The evaluation of the diet/disease relation in the EPIC study: considerations for the calibration and the disease models. *Int J Epidemiol* 2008;37:368–78.
 10. Schoenfeld D. Partial Residuals for The Proportional Hazards Regression Model. *Biometrika* 1982;69:239–41.
 11. Heinzl H, Kaider A. Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. *Comput Methods Programs Biomed* 1997;54:201–8.
 12. Lunn M, McNeil D. Applying Cox Regression to Competing Risks. *Biometrics* 1995;51:524–32.
 13. StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.
 14. Kabat GC, Matthews CE, Kamensky V, Hollenbeck AR, Rohan TE. Adherence to cancer prevention guidelines and cancer incidence, cancer mortality, and total mortality: a prospective cohort study. *Am J Clin Nutr* 2015;101:558–69.
 15. Sergentanis T, Kanavidis P, Michelakos T, Petridou E. Cigarette smoking and risk of lymphoma in adults. *European Journal of Cancer Prevention* 2013;22:131–50.
 16. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. *Inflamm res* 2008;57:497–503.

- Accepted Article
17. Epstein MM, Chang ET, Zhang Y, Fung TT, Batista JL, Ambinder RF, Zheng T, Mueller NE, Birmann BM. Dietary pattern and risk of hodgkin lymphoma in a population-based case-control study. *Am J Epidemiol* 2015;182:405–16.
 18. Solans M, Benavente Y, Saez M, Agudo A, Jakszyn P, Naudin S, Hosnijeh FS, Gunter M, Huybrechts I, Ferrari P, Besson C, Mahamat-Saleh Y, et al. Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. *Eur J Nutr [Internet]* 2019 [cited 2019 May 14];Available from: <https://doi.org/10.1007/s00394-019-01947-0>
 19. Solans M, Benavente Y, Saez M, Agudo A, Naudin S, Hosnijeh FS, Noh H, Freisling H, Ferrari P, Besson C, Mahamat-Saleh Y, Boutron-Ruault M-C, et al. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition. *Int J Cancer* 2019;145:122–31.
 20. Biggar RJ, Johansen JS, Smedby KE, Rostgaard K, Chang ET, Adami H-O, Glimelius B, Molin D, Hamilton-Dutoit S, Melbye M, Hjalgrim H. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. *Clin Cancer Res* 2008;14:6974–8.
 21. Abar L, Sobiecki JG, Cariolou M, Nanu N, Vieira AR, Stevens C, Aune D, Greenwood DC, Chan DSM, Norat T. Body size and obesity during adulthood, and risk of lympho-haematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies. *Ann Oncol* 2019;30:528–41.
 22. Bryant AJ, Newman JH. Alcohol intolerance associated with Hodgkin lymphoma. *CMAJ* 2013;185:E353.
 23. Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, Thiele J. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [Internet]. 2017 [cited 2018 Jul 9]. Available from: <http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017>

24. Baan R, Grosse Y, Straif K, Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part F: chemical agents and related occupations. *Lancet Oncol* 2009;10:1143–4.
25. Müller AMS, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. *Ann Hematol* 2005;84:1–12.

Table 1. Country-specific distribution of study participants, lymphoma cases and the Healthy Lifestyle Index (HLI) in the EPIC cohort.

					Lymphoma subgroups ²		NHL subgroups ²		BCL subgroups ²				
	Participants	PY	FUP ¹	Overall	NHL	HL	BCL	MT/NK	DLBCL	FL	CLL/SLL	MM/PCN	HLI ³
Denmark	53,577	794,546	16	613	569	28	493	23	119	74	115	122	11 (9-14)
France	64,086	829,048	15	219	207	11	196	8	39	41	43	42	13 (11-15)
Germany	48,002	498,396	12	227	211	13	168	11	29	20	39	55	12 (10-14)
Greece	24,687	266,336	11	60	56	3	36	2	2	3	12	15	11 (9-13)
Italy	44,274	627,018	15	296	272	15	216	11	37	32	44	73	11 (9-13)
Norway	29,689	395,178	14	146	141	5	115	14	22	27	23	23	13 (12-15)
Spain	39,855	635,751	17	239	220	14	192	10	33	27	51	51	12 (10-14)
Sweden	47,536	782,458	18	504	436	13	333	20	56	47	72	128	12 (10-14)
The Netherlands	30,555	430,017	15	167	160	6	143	8	37	24	29	38	13 (11-15)
United Kingdom	71,547	1,069,891	16	528	474	24	398	18	87	68	81	106	13 (11-15)
Total	453,808	6,328,639	15	2,999	2,746	132	2,290	125	461	363	509	653	12 (10-14)

Abbreviations: PY, person-years; FUP, follow-up (years); HLI, healthy lifestyle index; NL, The Netherlands; PY, person-years; UK: United Kingdoms; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; BCL, mature B-cell lymphoma; MT/NK, Mature T and natural killer-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia, small lymphocytic leukemia and prolymphocytic lymphocytic leukemia ; MM/PCN, plasma cell neoplasm and multiple myeloma.

¹ Median values;

² The groups of overall number of lymphoma, NHL and BCL also included lymphomas not otherwise specified (n=121), other NHL subtypes (n=331) and other BCL subtypes (n=304), respectively;

³ Means (25th-75th percentiles).

Table 2. Baseline characteristics¹ of the EPIC participants by quartiles of Healthy Lifestyle Index (HLI).

	Total cohort	HLI			
		Q1 [1 - 10]	Q2 [11 - 12]	Q3 [13 - 14]	Q4 [15 - 20]
Total participants (n)	453,808	129,429	111,358	110,730	102,291
Lymphoma cases (n)	2,999	937	734	718	610
Index components					
Smoking (% never)	45	15	40	56	74
Alcohol intake (g/day)	5 (1 - 15)	13 (3 - 30)	6 (1 - 15)	4 (1 - 11)	3 (0 - 7)
BMI (kg/m ²)	25 (22 - 28)	27 (24 - 30)	26 (22 - 28)	24 (22 - 27)	23 (22 - 25)
Diet score (units)	27 (23 - 32)	23 (20 - 27)	26 (22 - 30)	28 (24 - 33)	32 (28 - 36)
Physical activity (% active)	18	9	14	19	34
Covariates					
Sex (% women)	70	56	71	77	80
Age at recruitment (years)	52 (45 - 58)	52 (46 - 59)	52 (46 - 59)	51 (45 - 58)	50 (44 - 57)
Energy intake from food (kcal/day)	1,921 (1,572 - 2,339)	1,964 (1,597 - 2,401)	1,918 (1,568 - 2,337)	1,901 (1,559 - 2,308)	1,896 (1,565 - 2,296)
Height (cm)	165 (160 - 172)	167 (160 - 174)	165 (159 - 171)	165 (159 - 171)	165 (160 - 171)
Educational level (% higher education)	24	20	22	25	30

¹ Medians (25th - 75th percentiles) are presented for continuous variables, percentages for categorical variables.

Table 3. Hazard ratio estimates¹ for associations between the Healthy Lifestyle Index (HLI) (in quartiles and in continuous for a 1-SD increase²) and risks of lymphoma subtypes in the EPIC study.

	HLI				p _{wald} ³		1-SD increase	p _{trend} ³
	Q1 [1 - 10]	Q2 [11 - 12]	Q3 [13 - 14]	Q4 [15 - 20]				
All lymphomas (n=2,999)								
n	937	734	718	610				
HR (95% CI)	1.04 (0.94 - 1.14)	1.00 (Ref)	1.02 (0.92 - 1.13)	0.97 (0.87 - 1.08)	0.68		0.98 (0.94 - 1.01)	0.23

HL (n=132)							
n	53	36	22	21			
HR (95% CI)	1.21 (0.78 - 1.86)	1.00 (Ref)	0.64 (0.37 - 1.09)	0.64 (0.37 - 1.10)	0.03	0.78 (0.66 - 0.94)	7.3E-03
NHL (n=2,746)							
n	846	669	668	563			
HR (95% CI)	1.02 (0.92 - 1.14)	1.00 (Ref)	1.04 (0.93 - 1.16)	0.98 (0.88 - 1.10)	0.78	0.99 (0.95 - 1.03)	0.50
MT/NK (n=125)							
n	42	25	24	34			
HR (95% CI)	1.77 (0.62 - 5.01)	1.00 (Ref)	0.75 (0.49 - 1.14)	1.44 (0.85 - 2.44)	0.29	1.04 (0.86 - 1.26)	0.68
BCL (n=2,290)							
n	692	564	565	469			
HR (95% CI)	1.00 (0.89 - 1.11)	1.00 (Ref)	1.04 (0.93 - 1.17)	0.97 (0.85 - 1.09)	0.69	0.99 (0.95 - 1.04)	0.81
DLBCL (n=461)							
n	140	117	103	101			
HR (95% CI)	0.98 (0.76 - 1.25)	1.00 (Ref)	0.91 (0.7 - 1.19)	0.98 (0.75 - 1.28)	0.91	0.99 (0.90 - 1.09)	0.84
FL (n=363)							
n	88	92	97	86			
HR (95% CI)	0.82 (0.61 - 1.10)	1.00 (Ref)	1.04 (0.78 - 1.38)	0.98 (0.73 - 1.32)	0.44	1.04 (0.93 - 1.16)	0.49
CLL/SLL (n=509)							
n	171	100	127	111			
HR (95% CI)	1.33 (1.04 - 1.71)	1.00 (Ref)	1.35 (1.04 - 1.75)	1.34 (1.02 - 1.77)	0.08	1.05 (0.96 - 1.15)	0.28
MM/PCN (n=653)							
n	190	169	179	115			
HR (95% CI)	0.91 (0.74 - 1.13)	1.00 (Ref)	1.12 (0.91 - 1.38)	0.83 (0.65 - 1.05)	0.06	0.99 (0.91 - 1.07)	0.73
Other BCL⁴ (n=304)							
n	103	86	59	56			
HR (95% CI)	0.96 (0.72 - 1.29)	1.00 (Ref)	0.71 (0.51 - 0.99)	0.75 (0.53 - 1.06)	0.12	0.88 (0.79 - 1.00)	0.04


Abbreviations: HLI, Healthy Lifestyle Index; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; MT/NK, Mature T and natural killer-cell lymphoma; BCL, mature B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia, small lymphocytic leukemia and prolymphocytic lymphocytic leukemia ; MM/PCN, plasma cell neoplasm and multiple myeloma.

¹ Models were adjusted for education level, height, and non-alcohol energy intakes, and stratified by country, age in 1-year category, and sex;

² One standard deviation corresponded to 3 units in the HLI score;

³ P-values were determined using a Wald test for overall significance, according to a χ^2 distribution with three degrees of freedom for evaluation by quartiles, and one degree of freedom for evaluation in continuous.

⁴ Other BCL includes Burkitt lymphoma, hairy cell leukemia, lymphoplasmacytic lymphoma, Mantle cell lymphoma, marginal zone lymphoma, primary effusion lymphoma and prolymphocytic leukemia subtypes.



Applications in CAR T-cell Therapy: Dissecting Cellular Composition Using Single Cell Multiomics

Tuesday, March 24th (US)
5:00pm EST, 2:00pm PST
Wednesday, March 25th (AU)
8:00am AEDT

Free Webinar
Register Now

Sponsored by

Provided by



WILEY